Bicycle Therapeutics, the Cambridge biotech company, has done a collaboration deal with AstraZeneca which puts it in line for up to $1 billion. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Sir Gregory Winter (Master of Trinity College, Cambridge) and Prof Christian Heinis. Bicycle is pioneering a new class of drugs based on its bicyclic peptide platform, and will be working with AZ to spot and develop new treatments for respiratory, cardiovascular and metabolic diseases. More…
Home > LMB In The News > Master of Trinity’s Bicycle worth up to $1 billion